News
05-18-2012, 01:12 AM
A team from the Perelman School of Medicine and the Abramson Family Cancer Research Institute at the University of Pennsylvania found that the FDA-approved drug daclizumab improved the survival of breast cancer patients taking a cancer vaccine by 30 percent, compared to those patients not taking daclizumab. This proof-of-concept study is published this week in Science Translational Medicine...
More... (http://www.medicalnewstoday.com/releases/245507.php)
More... (http://www.medicalnewstoday.com/releases/245507.php)